Ceftaroline for Severe Methicillin-Resistant Staphylococcus aureus Infections: A Systematic Review

Abstract

Ceftaroline is approved by the Food and Drug Administration for acute bacterial skin and skin-structure infections and community-acquired bacterial pneumonia, including cases with concurrent bacteremia. Use for serious methicillin-resistant Staphylococcus aureus (MRSA) infections has risen for a multitude of reasons. The aim of this article is to review the literature evaluating clinical outcomes and safety of ceftaroline prescribed for serious MRSA infections. We conducted a literature search in Ovid (Medline) and PubMed for reputable case reports, clinical trials, and reviews focusing on the use of ceftaroline for treatment of MRSA infections. Twenty-two manuscripts published between 2010 and 2016 met inclusion criteria. Mean clinical cure was 74% across 379 patients treated with ceftaroline for severe MRSA infections. Toxicities were infrequent. Ceftaroline treatment resulted in clinical and microbiologic cure for severe MRSA infections. Close monitoring of hematological parameters is necessary with prolonged courses of ceftaroline.

Methicillin-Resistant Staphylococcus aureus Prosthetic Valve Endocarditis: Pathophysiology, Epidemiology, Clinical Presentation, Diagnosis, and Management

“…For cases of MRSA PVE with reduced vancomycin susceptibility (MIC Ͼ 1.0 g/ml), substantial toxicity, or failure of vancomycin, the optimal treatment is not established. Options include high-dose daptomycin (8 to 10 mg/kg once per day, if the isolate is daptomycin susceptible), linezolid, telavancin, ceftaroline, and daptomycin combined with ceftaroline, nafcillin, or fosfomycin, combinations that might result in synergy (159)(160)(161)(162)(163)(164)(165). Yet reported clinical experience with these treatments and combination therapies in MRSA PVE is limited.…”

Comparing the Outcomes of Ceftaroline Plus Vancomycin or Daptomycin Combination Therapy Versus Monotherapy in Adults with Complicated and Prolonged Methicillin-Resistant Staphylococcus Aureus Bacteremia Initially Treated with Supplemental Ceftaroline

“…The antibiotic later received additional approval for the solitary treatment of ABSSSI-associated bacteremia [7]. Ceftaroline's value in treating MRSA bacteremia secondary to non-ABSSSI causes such as infective endocarditis and osteomyelitis [8,9] led to its investigational use as a salvage measure for vancomycin-or daptomycin-refractory MRSA bacteremia [9,10]. Findings of bacteremia resolution plus in vitro evidence of antibiotic synergy [11,12] motivated others to follow suit.…”

Evaluation of Ceftaroline, Linezolid and Vancomycin in Vitro Susceptibility of Methicillin-Resistant Staphylococcus aureus and Coagulase-Negative Staphylococci Strains Isolated from Blood Cultures

“…Bununla birlikte, bu çalışmada S. aureus izolatlarında seftaroline direnç %2.9 oranında belirtilmiştir. Ağır kliniği olan MRSA enfeksiyonlarındaki başarı oranları üzerine yayınlanmış 22 makalenin sonuçları değerlendirildiğinde toplam 379 hastada ortalama klinik kür %74 olarak görülmüştür (32) . Farklı çalışmalarda elde edilen in vitro duyarlılık oranları da %93.3-94 olarak bildirilmektedir (33,34) .…”